JPH06506120A - ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 - Google Patents
ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体Info
- Publication number
- JPH06506120A JPH06506120A JP4509686A JP50968692A JPH06506120A JP H06506120 A JPH06506120 A JP H06506120A JP 4509686 A JP4509686 A JP 4509686A JP 50968692 A JP50968692 A JP 50968692A JP H06506120 A JPH06506120 A JP H06506120A
- Authority
- JP
- Japan
- Prior art keywords
- tnf
- antibody
- tnfα
- human
- region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
Abstract
Description
Claims (42)
- 1.ヒトの腫瘍壊死因子α(TNFα)に対する高親和性マウスモノクローナル 抗体であって、(a)抗体A2のTNFとの結合を競合的に阻害し、(b)ヒト TNFαの中和性エピトープに結合する抗体。
- 2.請求項1に記載のマウスモノクローナル抗体であって、検出可能にラベルさ れているもの。
- 3.ヒトの免疫グロブリンの不変領域の少なくとも一部と、ヒトのTNFαに特 異性を有するヒト以外の免疫グロブリンの可変部分の少なくとも一部を含むキメ ラ免疫グロブリン鎖。
- 4.請求項3に記載のキメラ免疫グロブリン鎖であって、H鎖とL鎖を有するも の。
- 5.請求項3に記載のキメラ免疫グロブリン鎖であって、不変領域がヒト起源の ものであるもの。
- 6.2個のL鎖と2個のH鎖を有し、そのおのおのが不変領域の少なくとも一部 と可変領域の少なくとも一部からなり、可変領域がヒトTNFαに対して特異性 を有し、生体内で、ヒトTNFαの中和作用を有するエピトープに高い親和性を もって結合するキメラ抗体分子。
- 7.請求項6に記載のキメラ抗体であって、TNFβに結合しないもの。
- 8.請求項6に記載のキメラ抗体であって、可変領域および不変領域がマウス起 源であるもの。
- 9.請求項6に記載のキメラ抗体であって、その可変領域がヒトTNFαの中和 作用を有するエピトープに結合する高親和性マウスモノクローナル抗体から誘導 されるもの。
- 10.請求項9に記載のキメラ抗体であって、該マウスモノクローナル抗体がA 2またはcA2のTNFαに対する結合を競合的に阻害するするもの。
- 11.請求項9に記載のキメラ抗体であって、該マウスモノクローナル抗体がA 2であるもの。
- 12.請求項6に記載のキメラ抗体であって、会合定数(Ka)で示される親和 性が少なくとも1×108l/molであるもの。
- 13.請求項6に記載のキメラ抗体であって、会合定数(Ka)で示される親和 性が少なくともl×109l/molであるもの。
- 14.請求項6に記載のキメラ抗体であって、少なくとも1μg/mlで、ID 50でヒトTNFαを中和するもの。
- 15.請求項6に記載のキメラ抗体であって、少なくとも100ng/mlでI D50でヒトTNFαを中和するもの。
- 16.請求項6に記載のキメラ抗体であって、少なくとも15ng/mlで、I D50でヒトTNFαを中和するもの。
- 17.請求項6に記載のキメラ抗体であって、検出可能にラベルされているもの 。
- 18.請求項1に記載のモノクローナル抗体であって、ハイプリドーマによりま たは組換えにより産生される検出可能にラベルされたもの。
- 19.請求項1に記載のモノクローナル抗体であって、hTNFαの残基87− 108、または59−80および87−108の両者と結合する抗原結合領域を 有するもの。
- 20.請求項1に記載のモノクローナル抗体であって、それ自身、そのフラグメ ント、または領域がSEQIDNO:1のhTNFαのアミノ酸11−13、3 7−42、49−57または155−157に含まれる1個以上のエピトープに 結合しないもの。
- 21.(a)モノクローナル抗体A2のマウスモノクローナル抗体、または(b )モノクローナル抗体cA2のマウス/ヒトーキメラモノクローナル抗体に相当 する抗TNF結合領域またはそのフラグメントを有する抗TNF抗体。
- 22.SEQIDNO:1のアミノ酸残基87−108または59−80および 87−108の両者からなる群から選ばれる少なくとも5個のアミノ酸からなる TNFペプチドであって、TNFのTNFレセプターへの結合を実質的に阻害す るように、レセプター結合配列と結合することによる抗TNF生物学的活性を有 する抗TNF抗体のエピトープを有するTNFポリペプチド。
- 23.請求項22に記載のTNFポリペプチドであって、実質的に、SEDID NO:1のアミノ酸59−80としての【配列があります】および SED ID NO:1のアミノ酸87−108として【配列があります】の少 なくとも一つの配列の3ないし22個のアミノ酸からなるTNFポリペプチド。
- 24.請求項1に記載の抗体もしくはそのフラグメント、領域部分、またはその 薬学的に許容されエステル、エーテル、硫酸塩,炭酸塩、グルクロン化物もしく はその塩、および薬学的に許容される担体からなる薬学的組成物。
- 25.単離TNFポリヌクレオチドであって、請求項6に記載の抗体をコードす るヌクレオチド配列からなり、該ヌクレオチド配列が、少なくとも一つの不変領 域との作動連関(連鎖)において少なくとも一つの不変領域をコードするヌクレ オチド配列からなるポリヌクレオチド。
- 26.請求項25に記載のポリヌクレオチドであって、ゲノムDNA配列または cDNA配列から選ばれるヌクレオチド配列を有するもの。
- 27.請求項25に記載のポリヌクレオチドであって、それ自身が発現担体であ るもの。
- 28.請求項25に記載のポリヌクレオチドで転換され、またはトランスフェク トされた宿主。
- 29.請求項28に記載の宿主であって、真核細胞または細菌細胞であるもの。
- 30.請求項29に記載の宿主であって、哺乳類の細胞であるもの。
- 31.請求項6に記載の抗体またはそのフラグメント、領域部分の製法であって 、 (a)請求項28に記載の宿主を抗体が回収可能の量で発現するように培養し、 (b)該抗体、またはそのフラグメント、領域部分を宿主または培養物から回収 することからなる製法。
- 32.TNFαによって仲介される疾患を有する患者の治療法であって、患者に 請求項24に記載の薬学的組成物の治療量を投与することからなる治療法。
- 33.TNFαによって仲介される疾患を有する患者の治療法であって、患者に 請求項42に記載の薬学的組成物の治療量を投与することからなる治療法。
- 34.試料からTNFαもしくはそのフラグメントまたは該TNFαを含む免疫 複合体から該TNFαを除去するための、(a)該試料を、請求項1に記載の抗 体またはそのフラグメント、領域部分であって、該TNFα、その部分または免 疫複合体が固定された抗体、フラグメント、または領域部分が可逆的に結合して 、結合したTNFα、その部分または免疫複合体を生成するように支持体に結合 されたもの、を含む手段と接触させ、 (b)該結合抗体、フラグメント、または領域部分から、結合したTNFα、そ の部分、または免疫複合体を回収することからなる方法。
- 35.試料からTNFαもしくはそのフラグメントまたは該TNFαを含む免疫 複合体から該TNFαを除去するための、(a)該試料を、請求項6に記載の抗 体またはそのフラグメント、領域部分であって、該TNFα、その部分または免 疫複合体が固定された抗体、フラグメント、または領域部分に可逆的に結合して 、結合したTNFα、その部分または免疫複合体を生成するように支持体に結合 されたもの、を含む装置と接触させ、 (b)該結合抗体、フラグメント、または領域部分から、結合したTNFα、そ の部分、または免疫複合体を回収することからなる方法。
- 36.体液中の高レベルのTNFαに関係する疾患または症状を有することを疑 われている患者を治療するための、 (a)請求項34に記載の方法によって、該体液から該TNFαを除去し、 (b)該体液を患者に戻すことからなる方法。
- 37.体液中の高レベルのTNFαに関係する疾患または症状を有することを疑 われている患者を治療するための、 (a)請求項35に配置の方法によって、該体液から該TNFαを除去し、 (b)該体液を患者に戻すことからなる方法。
- 38.試料中のヒトのTNFα検出する免疫検定方法であって、(a)該試料を 請求項1に記載の抗体、またはそのフラグメント、領域部分と接触させ、 (b)抗体と該TNFαの結合を検出することからなる方法。
- 39.試料中のヒトのTNFα検出する免疫検定方法であって、(a)該試料を 請求項6に記載の抗体、またはそのフラグメント、領域部分と接触させ、 (b)抗体と該TNFαの結合を検出することからなる方法。
- 40.請求項32に記載の患者の治療方法であって、該疾患が敗血症症候群、悪 液質、循環虚脱、急性および慢性の細菌感染、ウィルス感染、真菌感染によるシ ョック、紅斑性狼蒼、リウマチ性関節炎、アルコール誘発性肝炎、慢性炎症性疾 患、脈管炎症性疾患,GVH疾患、カイサキ病、および悪性疾患の一つである方 法。
- 41.請求項33に記載の患者の治療方法であって、該疾患が敗血症症候群、悪 液質、循環虚脱、急性および慢性の細菌感染、ウィルス感染,真菌感染によるシ ョック、紅斑性狼蒼、リウマチ性関節炎、アルコール誘発性肝炎、慢性炎症性疾 患、脈管炎症性疾患、GVH疾患、カイサキ病、および悪性疾患の一つである方 法。
- 42.請求項6に記載の抗体、もしくはそのフラグメント、領域部分、またはそ の薬学的に許容されるエステル、エーテル、硫酸塩、炭酸塩、グルコン化物もし くはその塩と、薬学的に許容できる担体からなる薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67082791A | 1991-03-18 | 1991-03-18 | |
US670,827 | 1991-03-18 | ||
PCT/US1992/002190 WO1992016553A1 (en) | 1991-03-18 | 1992-03-18 | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003436484A Division JP2004180686A (ja) | 1991-03-18 | 2003-12-10 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06506120A true JPH06506120A (ja) | 1994-07-14 |
Family
ID=24692048
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4509686A Withdrawn JPH06506120A (ja) | 1991-03-18 | 1992-03-18 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2003436484A Pending JP2004180686A (ja) | 1991-03-18 | 2003-12-10 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2007105234A Withdrawn JP2007254477A (ja) | 1991-03-18 | 2007-04-12 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2007105224A Withdrawn JP2007197457A (ja) | 1991-03-18 | 2007-04-12 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2008061505A Withdrawn JP2008195724A (ja) | 1991-03-18 | 2008-03-11 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2008061497A Withdrawn JP2008156371A (ja) | 1991-03-18 | 2008-03-11 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2011117072A Withdrawn JP2011155992A (ja) | 1991-03-18 | 2011-05-25 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2012004156A Pending JP2012087144A (ja) | 1991-03-18 | 2012-01-12 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003436484A Pending JP2004180686A (ja) | 1991-03-18 | 2003-12-10 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2007105234A Withdrawn JP2007254477A (ja) | 1991-03-18 | 2007-04-12 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2007105224A Withdrawn JP2007197457A (ja) | 1991-03-18 | 2007-04-12 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2008061505A Withdrawn JP2008195724A (ja) | 1991-03-18 | 2008-03-11 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2008061497A Withdrawn JP2008156371A (ja) | 1991-03-18 | 2008-03-11 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2011117072A Withdrawn JP2011155992A (ja) | 1991-03-18 | 2011-05-25 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
JP2012004156A Pending JP2012087144A (ja) | 1991-03-18 | 2012-01-12 | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 |
Country Status (13)
Country | Link |
---|---|
EP (6) | EP1681305A3 (ja) |
JP (8) | JPH06506120A (ja) |
AT (2) | ATE201234T1 (ja) |
AU (1) | AU668864B2 (ja) |
CA (2) | CA2106299C (ja) |
DE (7) | DE69233701T2 (ja) |
DK (2) | DK1097945T3 (ja) |
ES (2) | ES2156859T5 (ja) |
GR (1) | GR3036375T3 (ja) |
HK (1) | HK1037923A1 (ja) |
LU (1) | LU90854I2 (ja) |
NL (1) | NL300069I2 (ja) |
WO (1) | WO1992016553A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001302542A (ja) * | 2000-04-14 | 2001-10-31 | Tanabe Seiyaku Co Ltd | ベーチェット病治療剤 |
JP2006507286A (ja) * | 2002-10-24 | 2006-03-02 | アボツト・バイオテクノロジー・リミテツド | TNFα活性が有害である疾患を治療するための低用量方法 |
JP2009102390A (ja) * | 2009-01-21 | 2009-05-14 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
JPWO2009142186A1 (ja) * | 2008-05-20 | 2011-09-29 | 株式会社カネカ | 細胞障害性組成物 |
JP2012092147A (ja) * | 2012-02-07 | 2012-05-17 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
JP2014055182A (ja) * | 2013-12-20 | 2014-03-27 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
US11986523B2 (en) | 2017-01-11 | 2024-05-21 | Celltrion Inc. | Stable liquid formula comprising anti-TNFa antibody, acetate buffer, and glycine |
Families Citing this family (152)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GB9109645D0 (en) * | 1991-05-03 | 1991-06-26 | Celltech Ltd | Recombinant antibodies |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
US5919452A (en) * | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
WO1992016553A1 (en) | 1991-03-18 | 1992-10-01 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US5656272A (en) * | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
IT1254315B (it) * | 1992-03-27 | 1995-09-14 | Mini Ricerca Scient Tecnolog | Anticorpi monoclonali anti-idiotipici diretti contro anticorpi anti-tnf. |
EP0585705B1 (en) * | 1992-08-28 | 1998-11-04 | Bayer Corporation | Use of monoclonal antibodies to TNF to treat bacterial meningitis |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
US6863890B1 (en) | 1993-02-26 | 2005-03-08 | Advanced Biotherapy, Inc. | Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha |
US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
NZ266838A (en) | 1993-06-03 | 1997-02-24 | Therapeutic Antibodies Inc | Treatment of patients with anti-tnfalpha antibody, antibody fragment |
CA2097952C (en) * | 1993-06-08 | 2006-03-14 | Alex D. Romaschin | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
NZ278607A (en) * | 1994-02-07 | 1999-05-28 | Knoll Ag | Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above |
US5804370A (en) * | 1994-06-08 | 1998-09-08 | Critichem Medical Products Limited | Early diagnosis of sepsis utilizing antigen-antibody interactions amplified by whole blood chemiluminescence |
US6203997B1 (en) | 1994-06-08 | 2001-03-20 | Sepsis, Inc. | Quantitation of analytes in whole blood |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
US20140212413A1 (en) * | 1995-12-11 | 2014-07-31 | New York University | Methods of Treating TNF-alpha-Mediated Diseases Using Chimeric TNF-alpha Antibodies |
NZ512006A (en) | 1996-02-09 | 2005-05-27 | Abbott Biotech Ltd | Medical treatment with human TNF-alpha antibodies |
US7608262B2 (en) * | 1996-02-16 | 2009-10-27 | The Kennedy Institute Of Rheumatology | Methods of preventing or treating thrombosis with tumor necrosis factor antagonists |
WO1998011917A1 (en) * | 1996-09-19 | 1998-03-26 | Centocor, Inc. | Hiv-1 therapy with il-2 and anti-tnf antibody |
DK0936923T3 (da) * | 1996-11-15 | 2004-04-26 | Kennedy Inst Of Rheumatology | Undertrykkelse af TNFalpha og IL-12 ved terapi |
CA2282501A1 (en) * | 1997-02-19 | 1998-08-27 | Centocor, Inc. | Sustained drug delivery and compositions useful therefor |
AU7345798A (en) * | 1997-05-12 | 1998-12-08 | Kennedy Institute Of Rheumatology, The | Suppression of tumor necrosis factor alpha and vascular endothelial growth factor in therapy |
US6159683A (en) * | 1997-12-16 | 2000-12-12 | Spectral Diagnostics, Inc. | Method of determining stage of sepsis |
EP1022027A1 (en) * | 1999-01-22 | 2000-07-26 | Applied Research Systems ARS Holding N.V. | Tumor necrosis factor antagonists and their use in endometriosis |
JP2002538170A (ja) * | 1999-03-02 | 2002-11-12 | セントコール, インコーポレイテッド | 喘息の治療における抗−TNFα抗体 |
US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
AU2002254234A1 (en) * | 2001-03-14 | 2002-09-24 | Centocor, Inc. | Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses |
CA2868614A1 (en) | 2001-06-08 | 2002-12-08 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
CA2466592A1 (en) * | 2001-11-12 | 2003-05-22 | Koen Hellendoorn | Modified anti-tnf alpha antibody |
US20030206898A1 (en) | 2002-04-26 | 2003-11-06 | Steven Fischkoff | Use of anti-TNFalpha antibodies and another drug |
US20070202104A1 (en) * | 2002-07-19 | 2007-08-30 | Abbott Laboratories S.A. | Treatment of spondyloarthropathies using TNFalpha inhibitors |
US8715664B2 (en) | 2005-05-16 | 2014-05-06 | Abbvie Biotechnology Ltd. | Use of human TNFα antibodies for treatment of erosive polyarthritis |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
US7285269B2 (en) | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005082377A1 (ja) | 2004-03-01 | 2005-09-09 | Ajinomoto Co., Inc. | 抗ヒトTNF-α抗体活性低下抑制剤 |
EP2423331B1 (en) | 2004-03-31 | 2019-05-08 | The General Hospital Corporation | Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments |
TWI439284B (zh) | 2004-04-09 | 2014-06-01 | Abbvie Biotechnology Ltd | 用於治療TNFα相關失調症之多重可變劑量療法 |
EP1919951B1 (en) * | 2005-08-04 | 2015-01-28 | Janssen Biotech, Inc. | Anti-tnf-alpha antibodies and methods of use |
JP4861019B2 (ja) * | 2006-01-31 | 2012-01-25 | 独立行政法人科学技術振興機構 | ヒトTNF−αに対する抗体酵素およびその利用 |
CA2647029A1 (en) | 2006-04-05 | 2007-10-18 | Abbott Biotechnology Ltd. | Antibody purification |
US9605064B2 (en) | 2006-04-10 | 2017-03-28 | Abbvie Biotechnology Ltd | Methods and compositions for treatment of skin disorders |
EP2010214A4 (en) | 2006-04-10 | 2010-06-16 | Abbott Biotech Ltd | USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS |
WO2008063213A2 (en) | 2006-04-10 | 2008-05-29 | Abbott Biotechnology Ltd. | Uses and compositions for treatment of psoriatic arthritis |
SG10201510384UA (en) | 2006-09-13 | 2016-01-28 | Abbvie Inc | Cell culture improvements |
WO2008141176A1 (en) | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
EA200971050A1 (ru) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений |
EP2171451A4 (en) | 2007-06-11 | 2011-12-07 | Abbott Biotech Ltd | METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS |
EP2193145A4 (en) | 2007-08-28 | 2011-05-18 | Abbott Biotech Ltd | COMPOSITIONS AND METHODS COMPRISING BINDING PROTEINS FOR ADALIMUMAB |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
SG187473A1 (en) | 2008-01-15 | 2013-02-28 | Abbott Gmbh & Co Kg | Powdered protein compositions and methods of making same |
KR20110014607A (ko) | 2008-04-29 | 2011-02-11 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
US8962629B2 (en) | 2008-06-10 | 2015-02-24 | Abbvie Inc. | Tricyclic compounds |
SG192489A1 (en) | 2008-07-08 | 2013-08-30 | Abbott Lab | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
EP2228652A1 (en) | 2009-03-11 | 2010-09-15 | Medizinische Universität Wien | Improvement of tumour treatment |
WO2011015916A2 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | Vectors and compounds for expression of recombinant infliximab |
SG178930A1 (en) | 2009-08-29 | 2012-04-27 | Abbott Lab | Therapeutic dll4 binding proteins |
WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
EP2506713A4 (en) | 2009-12-01 | 2014-09-03 | Abbvie Inc | NEW TRICYCLIC COMPOUNDS |
HUE033099T2 (en) | 2009-12-01 | 2017-11-28 | Abbvie Inc | New tricyclic compounds |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
CL2010000019A1 (es) * | 2010-01-11 | 2010-06-11 | Univ Chile | Anticuerpo monoclonal contra el tnf humano y sus fragmentos, secuencias nucleotidicas que lo codifican, vector de expresion y celulas que las contienen, composiciones y kit que comprenden el anticuerpo, uso de los mismos y metodo para su obtencion. |
CA2787755A1 (en) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
US9023997B2 (en) | 2010-01-20 | 2015-05-05 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
EP3680253A3 (en) | 2010-03-02 | 2020-09-30 | AbbVie Inc. | Therapeutic dll4 binding proteins |
CN105056232A (zh) | 2010-06-03 | 2015-11-18 | 阿布维生物技术有限公司 | 用于治疗化脓性汗腺炎(hs)的用途和组合物 |
PE20131412A1 (es) | 2010-08-03 | 2014-01-19 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN104531671A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
CN102675460B (zh) | 2011-02-28 | 2015-08-19 | 珠海市丽珠单抗生物技术有限公司 | 抗肿瘤坏死因子α的人源化抗体 |
US8658171B2 (en) | 2011-02-28 | 2014-02-25 | Livzon Mabpharm Inc. | Humanized anti-TNFα antibodies |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
CA2839755A1 (en) | 2011-06-17 | 2012-12-20 | President And Fellows Of Harvard College | Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer |
WO2013003697A1 (en) | 2011-06-30 | 2013-01-03 | Trustees Of Boston University | Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1) |
CA2843315A1 (en) * | 2011-08-01 | 2013-02-07 | Avaxia Biologics, Inc. | Bovine polyclonal antibody specific for human tnf |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
EP3492109B1 (en) | 2011-10-03 | 2020-03-04 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
EP2791170A1 (en) | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
MX2014008101A (es) | 2011-12-30 | 2014-09-25 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17. |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US8999380B2 (en) | 2012-04-02 | 2015-04-07 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of biologics and proteins associated with human disease |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
EP2890782A1 (en) | 2012-09-02 | 2015-07-08 | AbbVie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
WO2014071074A2 (en) | 2012-11-01 | 2014-05-08 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
US9597380B2 (en) | 2012-11-26 | 2017-03-21 | Modernatx, Inc. | Terminally modified RNA |
CA2905010A1 (en) | 2013-03-12 | 2014-09-18 | Abbvie Inc. | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
PL2970980T3 (pl) * | 2013-03-15 | 2019-01-31 | Janssen Biotech, Inc | Sposoby wytwarzania kontrolujące zawartość C-końcowej lizyny, galaktozy i kwasu sjalowego w rekombinowanych białkach |
EP2970459A2 (en) | 2013-03-15 | 2016-01-20 | AbbVie Inc. | Dual specific binding proteins directed against il-1beta and il-17 |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US9937231B2 (en) | 2013-03-27 | 2018-04-10 | The General Hospital Corporation | Methods and agents for treating Alzheimer's disease |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
BR112016007255A2 (pt) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polinucleotídeos que codificam receptor de lipoproteína de baixa densidade |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
WO2015135884A1 (en) | 2014-03-10 | 2015-09-17 | Richter Gedeon Nyrt. | Immunoglobulin purification using pre-cleaning steps |
EP3194581A4 (en) | 2014-09-15 | 2018-04-25 | Children's Medical Center Corporation | Methods and compositions to increase somatic cell nuclear transfer (scnt) efficiency by removing histone h3-lysine trimethylation |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
EP3078675A1 (en) | 2015-04-10 | 2016-10-12 | Ares Trading S.A. | Induction dosing regimen for the treatment of tnf alpha mediated disorders |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
HU231463B1 (hu) | 2015-08-04 | 2024-01-28 | Richter Gedeon Nyrt. | Módszer rekombináns proteinek galaktóz tartalmának növelésére |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN116284011A (zh) | 2015-10-16 | 2023-06-23 | 艾伯维公司 | 制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法 |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10465003B2 (en) | 2016-02-05 | 2019-11-05 | Janssen Biotech, Inc. | Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes |
EP3573658A4 (en) | 2017-01-30 | 2021-07-21 | Janssen Biotech, Inc. | ANTI-TNF ANTIBODIES, COMPOSITIONS, AND METHODS FOR TREATMENT OF ACTIVE PSORIATIC ARTHRITIS |
MX2019009377A (es) | 2017-02-07 | 2019-12-11 | Janssen Biotech Inc | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa. |
TW202026035A (zh) | 2018-08-29 | 2020-07-16 | 美商再生元醫藥公司 | 用來治療患有類風濕性關節炎之個體的方法及組成物 |
HU231514B1 (hu) | 2018-11-07 | 2024-07-28 | Richter Gedeon Nyrt | Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer |
KR20210122810A (ko) | 2019-01-31 | 2021-10-12 | 사노피 바이오테크놀로지 | 청소년 특발성 관절염을 치료하기 위한 항 il-6 수용체 항체 |
HU231498B1 (hu) | 2019-04-04 | 2024-05-28 | Richter Gedeon Nyrt | Immunglobulinok affinitás kromatográfiájának fejlesztése kötést megelőző flokkulálás alkalmazásával |
EP3972690A4 (en) | 2019-05-23 | 2023-07-05 | Janssen Biotech, Inc. | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING COMBINATION THERAPY OF ANTIBODIES TO IL-23 AND TNF-ALPHA |
US20240270859A1 (en) | 2020-12-09 | 2024-08-15 | Hk Inno.N Corporation | ANTI-OX40L ANTIBODY, ANTI-OX40L/ANTI-TNFa BISPECIFIC ANTIBODY, AND USES THEREOF |
WO2024054934A1 (en) | 2022-09-07 | 2024-03-14 | Mdx Management Llc | Shp-1 inhibitors for treating cancer |
WO2024097804A1 (en) | 2022-11-02 | 2024-05-10 | Mdx Management Llc | Combination of a tyrosine kinase inhibitor and a pro-inflammatory agent for treating cancer |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3631229A1 (de) * | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US5075236A (en) * | 1987-04-24 | 1991-12-24 | Teijin Limited | Method of detecting kawasaki disease using anti-tumor necrosis antibody |
DE3823804A1 (de) * | 1988-07-14 | 1990-01-18 | Basf Ag | Neutralisation der in vitro und in vivo toxischen eigenschaften von tnf-(alpha) durch monoklonale antikoerper und den davon abgeleiteten fragmenten |
JP2638652B2 (ja) * | 1988-07-18 | 1997-08-06 | カイロン・コーポレーション | カケクチンと反応するモノクロナール抗体 |
PT92900A (pt) * | 1989-01-24 | 1990-07-31 | Sistema de vectores de expressao para a producao de anticorpos monoclonais quimericos | |
EP0486526B2 (en) * | 1989-08-07 | 2001-03-07 | Peptech Limited | Tumour necrosis factor binding ligands |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
WO1992016553A1 (en) | 1991-03-18 | 1992-10-01 | New York University | Monoclonal and chimeric antibodies specific for human tumor necrosis factor |
-
1992
- 1992-03-18 WO PCT/US1992/002190 patent/WO1992016553A1/en active IP Right Grant
- 1992-03-18 DE DE69233701T patent/DE69233701T2/de not_active Expired - Lifetime
- 1992-03-18 AT AT92910625T patent/ATE201234T1/de active
- 1992-03-18 CA CA002106299A patent/CA2106299C/en not_active Expired - Lifetime
- 1992-03-18 DK DK00204461T patent/DK1097945T3/da active
- 1992-03-18 DE DE2001199067 patent/DE10199067I2/de active Active
- 1992-03-18 ES ES92910625T patent/ES2156859T5/es not_active Expired - Lifetime
- 1992-03-18 DE DE07012625T patent/DE07012625T1/de active Pending
- 1992-03-18 ES ES00204461T patent/ES2289997T3/es not_active Expired - Lifetime
- 1992-03-18 AU AU17649/92A patent/AU668864B2/en not_active Expired
- 1992-03-18 DE DE07006112T patent/DE07006112T1/de active Pending
- 1992-03-18 DE DE69231828T patent/DE69231828T3/de not_active Expired - Lifetime
- 1992-03-18 AT AT00204461T patent/ATE366316T1/de active
- 1992-03-18 DE DE07012626T patent/DE07012626T1/de active Pending
- 1992-03-18 EP EP06001779A patent/EP1681305A3/en not_active Withdrawn
- 1992-03-18 CA CA2736076A patent/CA2736076A1/en not_active Abandoned
- 1992-03-18 EP EP07006112A patent/EP1857553A1/en not_active Withdrawn
- 1992-03-18 DK DK92910625T patent/DK0610201T4/da active
- 1992-03-18 JP JP4509686A patent/JPH06506120A/ja not_active Withdrawn
- 1992-03-18 DE DE06001779T patent/DE06001779T1/de active Pending
- 1992-03-18 EP EP00204461A patent/EP1097945B1/en not_active Expired - Lifetime
- 1992-03-18 EP EP07012625A patent/EP1905782A1/en not_active Withdrawn
- 1992-03-18 EP EP92910625A patent/EP0610201B2/en not_active Expired - Lifetime
- 1992-03-18 EP EP07012626A patent/EP1857554A1/en not_active Withdrawn
-
2001
- 2001-08-10 GR GR20010401231T patent/GR3036375T3/el unknown
- 2001-11-09 HK HK01107917A patent/HK1037923A1/xx not_active IP Right Cessation
- 2001-11-13 LU LU90854C patent/LU90854I2/fr unknown
- 2001-11-14 NL NL300069C patent/NL300069I2/nl unknown
-
2003
- 2003-12-10 JP JP2003436484A patent/JP2004180686A/ja active Pending
-
2007
- 2007-04-12 JP JP2007105234A patent/JP2007254477A/ja not_active Withdrawn
- 2007-04-12 JP JP2007105224A patent/JP2007197457A/ja not_active Withdrawn
-
2008
- 2008-03-11 JP JP2008061505A patent/JP2008195724A/ja not_active Withdrawn
- 2008-03-11 JP JP2008061497A patent/JP2008156371A/ja not_active Withdrawn
-
2011
- 2011-05-25 JP JP2011117072A patent/JP2011155992A/ja not_active Withdrawn
-
2012
- 2012-01-12 JP JP2012004156A patent/JP2012087144A/ja active Pending
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001302542A (ja) * | 2000-04-14 | 2001-10-31 | Tanabe Seiyaku Co Ltd | ベーチェット病治療剤 |
JP2006507286A (ja) * | 2002-10-24 | 2006-03-02 | アボツト・バイオテクノロジー・リミテツド | TNFα活性が有害である疾患を治療するための低用量方法 |
JP2012021001A (ja) * | 2002-10-24 | 2012-02-02 | Abbott Biotechnology Ltd | TNFα活性が有害である疾患を治療するための低用量方法 |
JP2015028040A (ja) * | 2002-10-24 | 2015-02-12 | アッヴィ バイオテクノロジー リミテッド | TNFα活性が有害である疾患を治療するための低用量方法 |
JPWO2009142186A1 (ja) * | 2008-05-20 | 2011-09-29 | 株式会社カネカ | 細胞障害性組成物 |
JP2009102390A (ja) * | 2009-01-21 | 2009-05-14 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
JP2012092147A (ja) * | 2012-02-07 | 2012-05-17 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
JP2014055182A (ja) * | 2013-12-20 | 2014-03-27 | Mitsubishi Tanabe Pharma Corp | ベーチェット病治療剤 |
US11986523B2 (en) | 2017-01-11 | 2024-05-21 | Celltrion Inc. | Stable liquid formula comprising anti-TNFa antibody, acetate buffer, and glycine |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH06506120A (ja) | ヒト腫瘍壊死因子に特異的なモノクローナルなキメラ抗体 | |
US7227003B2 (en) | Anti-TNF antibody fragments | |
JP3780315B2 (ja) | 炎症性疾患の処置のための抗il−8モノクローナル抗体 | |
WO2018177393A1 (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
WO2006065975A2 (en) | Methods of treating ankylosing spondylitis using anti-tnf antibodies and peptides of human tumor necrosis factor | |
JP2007045831A (ja) | Il4抗体およびその使用 | |
EP0840620B1 (en) | Il-8 antagonists for treatment of asthma | |
EP0576439B1 (en) | Monoclonal antibody against lps core | |
US5858728A (en) | Monoclonal antibody against LPS core | |
AU2012277185A1 (en) | Soluble integrin alpha4 mutant | |
CA2324853C (en) | Monoclonal and chimeric antibodies specific for human tumor necrosis factor | |
EP0672120B1 (en) | Production of human monoclonal antibodies active against hepatitis b surface antigen | |
JPH11503752A (ja) | 抗tnf抗体の複数回投与 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20031210 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20041201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050809 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050812 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051118 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20070320 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20070320 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20070320 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20080908 |